Please login to the form below
IDT Biologika
This page shows the latest IDT Biologika news and features for those working in and with pharma, biotech and healthcare.
AZ partners with IDT Biologika to bolster manufacturing for COVID-19 vaccine in EU
AZ is looking to accelerate vaccine output in Q2 2021. AstraZeneca (AZ) has linked up with IDT Biologika to increase manufacturing of its Oxford University-partnered COVID-19 vaccine in the ... We are delighted to be investing with our partner IDT
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
-
B2B media account director
-
Competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Omicron rise prompts tougher measures in England
- Pfizer/BioNTech promote booster against Omicron
- What is EVID AI?
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- AstraZeneca and Ionis sign $3.6bn deal for eplontersen
- Roche’s Actemra approved for severe COVID-19 in Europe
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Sanofi to buy acne specialist Origimm
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Promoting off-label use: where to draw the line?
- Synairgen’s SNG001 advances into phase 3 COVID-19 trial
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- ...
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
